Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.22
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell